Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
32.52
-1.68 (-4.91%)
At close: Nov 6, 2026, 4:00 PM EST
32.68
+0.16 (0.48%)
After-hours: Nov 6, 2026, 7:59 PM EST
Castle Biosciences Revenue
Castle Biosciences had revenue of $102.89M in the quarter ending September 30, 2026, with 23.90% growth. This brings the company's total for the last twelve months to $377.13M, up 9.78% year-over-year. In the year 2025, Castle Biosciences had annual revenue of $344.23M with 3.66% growth. That makes Castle Biosciences the 12,996th largest company in the world by revenue and 2,466th in the United States.
Revenue (ttm)
$377.13M
Revenue Growth
+9.78%
P/S Ratio
2.66
Revenue / Employee
$359,853
Employees
1,048
Market Cap
1.00B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 344.23M | 12.16M | 3.66% |
| Dec 31, 2024 | 332.07M | 112.28M | 51.09% |
| Dec 31, 2023 | 219.79M | 82.75M | 60.38% |
| Dec 31, 2022 | 137.04M | 42.95M | 45.65% |
| Dec 31, 2021 | 94.09M | 31.44M | 50.18% |
| Dec 31, 2020 | 62.65M | 10.78M | 20.79% |
| Dec 31, 2019 | 51.87M | 29.08M | 127.62% |
| Dec 31, 2018 | 22.79M | 9.03M | 65.67% |
| Dec 31, 2017 | 13.75M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sotera Health Company | 1.23B |
| Myriad Genetics | 803.60M |
| NeoGenomics | 787.75M |
| OPKO Health | 654.10M |
| Veracyte | 581.78M |
| CareDx | 497.40M |
| GeneDx Holdings | 454.43M |
| Fulgent Genetics | 323.93M |
CSTL News
- 2 days ago - Castle Biosciences price target raised to $40 from $35 at KeyBanc - TheFly
- 2 days ago - Castle Biosciences price target raised to $39 from $38 at Baird - TheFly
- 2 days ago - Castle Biosciences reports Q3 adjusted EPS (13c), consensus (35c) - TheFly
- 2 days ago - Castle Biosciences raises 2026 revenue view to $385M-$395M from $345M-$355M - TheFly
- 2 days ago - Castle Biosciences Earnings Call Transcript: Q3 2026 - Transcripts
- 2 days ago - Castle Biosciences Earnings release: Q3 2026 - Filings
- 2 days ago - Castle Biosciences Quarterly report: Q3 2026 - Filings
- 2 days ago - Castle Biosciences Slides: Q3 2026 - Filings